Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. - Wikidata - wikimedia - TriplyDB

Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study.

Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study.

http://www.wikidata.org/entity/Q35584556

about

Breast cancer and sexual function Multidisciplinary overview of vaginal atrophy and associated genitourinary symptoms in postmenopausal women Immunolocalization of steroidogenic enzymes in the vaginal mucous of Galea spixii during the estrous cycle.A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy Interventions to address sexual problems in people with cancer Caring for the breast cancer survivor's health and well-being.Breast cancer, aromatase inhibitor therapy, and sexual functioning: a pilot study of the effects of vaginal testosterone therapy Advances in pharmacotherapy for treating female sexual dysfunction.Improving patients' understanding of terms and phrases commonly used in self-reported measures of sexual function.An update on drugs for the treatment of menopausal symptoms.Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue.Vaginal Estrogen Therapy for Patients with Breast Cancer.The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI.An update on the pharmacological management of female sexual dysfunction.Androgen therapy in women, beyond libido.Treatment of vaginal atrophy.Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.Management of menopause in women with breast cancer.Safety of aromatase inhibitor therapy in breast cancer.Vaginal Health During Breast Cancer Treatment.Management of Potential Long-Term Toxicities in Breast Cancer Patients.Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy.Effects of long-term high dose testosterone administration on vaginal epithelium structure and estrogen receptor-α and -β expression of young women.Sexual function and sex hormones in breast cancer patients.A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer.Female Sexual Dysfunction and Premature Menopause with Focus on Women’s Wording

P2860

Q26773714-AE67E87E-FA01-408E-9682-5475B415312B Q26828795-CD770ED9-A224-4C94-9C65-40866C42E01E Q33602152-C08AE231-B3BC-4544-808C-0C40815F75FB Q33605919-C1483D4E-A9FE-4E96-82BF-5617785CD06B Q33840155-1679BB01-9BD3-4694-BF29-C4C0EC92F477 Q34031251-0782E3E5-DC9B-4E60-BEA5-00857AF7F40E Q34286594-DE723B25-F6C9-4E12-BABD-182E36DAA28D Q34465301-69BB3E84-90F2-4D10-AFB2-1D523D99DBB1 Q34590345-F2C9FBB2-205C-42FA-91AE-9C765B39A98F Q35784054-6619C17F-A509-4A1F-8746-7E075EC1964F Q35824414-3CDE3246-2613-4A39-9254-C9C2E64CB132 Q37389691-B9F9923B-6805-4BA5-AEFB-B23FCBA8C471 Q38011784-AA75EB5D-CEB9-4023-B016-3BEF44DBAB0B Q38044019-7C791F82-BE6B-4616-99D1-29617B679316 Q38104425-12C2AD96-F822-4112-BDB9-0F50A4525430 Q38193877-07AF443F-C42E-49AF-BDD8-60826A55D888 Q38232774-92697786-3E84-48E6-AB63-1518AC6DC556 Q38298951-5C26813C-12C5-49CD-B171-838A5AAD5A99 Q38522924-728ACEEB-C94C-4299-8025-28DC87A9EF34 Q38807445-7609DDE2-B7B3-4AB1-8B12-385E15A5A481 Q39305824-41FBB9AB-9B92-440D-A524-01CBA3BCD9EF Q45898328-2DF99744-94D6-4CC1-9FFF-05B9DCCF10AB Q45899500-188514EB-6F62-4E18-8F31-14276F7C7B92 Q47579508-454C519F-87A6-4388-B333-15D96857C0C5 Q53779463-5BFEB876-6CFE-4950-B41A-330720AA3F62 Q57345846-63D40373-83DC-4B5F-B65D-0F23EAAE1BAD

P2860

Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study.

http://www.wikidata.org/entity/Q35584556

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Topical testosterone for breas ...... nhibitors: a phase I/II study.

@ast

Topical testosterone for breas ...... nhibitors: a phase I/II study.

@en

type

label

Topical testosterone for breas ...... nhibitors: a phase I/II study.

@ast

Topical testosterone for breas ...... nhibitors: a phase I/II study.

@en

prefLabel

Topical testosterone for breas ...... nhibitors: a phase I/II study.

@ast

Topical testosterone for breas ...... nhibitors: a phase I/II study.

@en

P1433

Q35584556-0A1AD343-AD87-4D02-A1AE-8F1302B0F946

P1476

Q35584556-4A4A8344-9A8C-4996-BB2F-13296F7BDBF6

P2093

Q35584556-17FCE2AD-F931-47B6-A5B4-422C17CE5C2B

Q35584556-1CC21C42-029C-46F8-9A4E-F7B25163AAF6

Q35584556-2A4D1965-B7B3-49C8-9B81-F6746D877A14

Q35584556-521F53D8-D536-483C-B8C9-3153A7145B7B

Q35584556-BB26C872-623E-4D64-A181-FC187D142096

Q35584556-D745D49D-201F-4B47-ADB7-3A772A88DFFC

Q35584556-DD217AAD-BC4E-4C6B-9F6A-D0C11391222A

P2860

Q35584556-0CEFF3CB-BF32-4485-9927-FEC08EB9EDAC

Q35584556-2C1A8559-3C31-4C81-A517-C8E2226CF7BE

Q35584556-31FE53D7-027D-499E-9735-0AD7D170CB74

Q35584556-3AB5A7FC-FC43-449E-9CF5-EC6A0AE77223

Q35584556-3B2AD965-55B7-4F11-AFF2-5798CE1BD68C

Q35584556-572E814D-C1EA-4C64-80D2-63512037FA5C

Q35584556-5AE44193-3F93-4603-BABB-978D87C4DB89

Q35584556-612FD088-BC27-4CDA-9A37-BBEE1A1E0677

Q35584556-6A99EEE8-166B-4E66-8E8E-9E08E4D99A3F

Q35584556-6B660CC6-FB3C-4056-A87D-9E3FEE7C7DA6

P304

Q35584556-4EF7D046-86DB-4F72-9A82-C8C0C463D40F

P31

Q35584556-AB97F714-41D2-412E-955B-A0E7F1E9C0AA

P356

Q35584556-B80CAC0E-0BCB-40B2-82B3-C037A74EE6D2

P433

Q35584556-F38B7EA0-31B2-48CE-8043-1C42E187ABB3

P478

Q35584556-CAE57BB5-A7AC-4C13-A68B-8558EF82DB0F

P50

Q35584556-9A7D21C0-450C-4DFC-AB62-62AAAE9CBB95

P577

Q35584556-570F738A-D708-471F-8A7C-488476C62652

P5875

Q35584556-1847EF3A-2AC9-49B6-B5E4-FFA09A5DB9D6

P698

Q35584556-7650F360-33F9-4A4F-9DB7-DF08A4BFD316

P932

Q35584556-376F3D26-D0DA-4012-83F9-9FCF8157014D

P356

THEONCOLOGIST.2010-0435

P1433

P1476

Topical testosterone for breas ...... inhibitors: a phase I/II study

@en

P2093

Charles D Maclean

http://www.w3.org/2001/XMLSchema#string

Hyman Muss

http://www.w3.org/2001/XMLSchema#string

Julia Johnson

http://www.w3.org/2001/XMLSchema#string

Laurence Demers

http://www.w3.org/2001/XMLSchema#string

Marie Wood

http://www.w3.org/2001/XMLSchema#string

Sabrina Witherby

http://www.w3.org/2001/XMLSchema#string

Sharon Mount

http://www.w3.org/2001/XMLSchema#string

P2860

Local oestrogen for vaginal atrophy in postmenopausal women

Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms

Toxicity and response criteria of the Eastern Cooperative Oncology Group

To block estrogen's synthesis or action: that is the question.

Transdermal testosterone treatment in women with impaired sexual function after oophorectomy.

Testosterone effects on the breast: implications for testosterone therapy for women.

Aromatase inhibitors in breast cancer.

The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: cytomorphology versus computerised cytometry

Management of post-menopausal vaginal atrophy and atrophic vaginitis.

Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer.

P304

424-431

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2010-0435

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Benjamin Littenberg

P577

2011-03-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50347931

http://www.w3.org/2001/XMLSchema#string

P698

21385795

http://www.w3.org/2001/XMLSchema#string

P932

3228118

http://www.w3.org/2001/XMLSchema#string